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Interpreting the impact of noncoding structural variation
in neurodevelopmental disorders
Eva D’haene, MSc1 and Sarah Vergult, PhD1
The emergence of novel sequencing technologies has greatly
improved the identification of structural variation, revealing that a
human genome harbors tens of thousands of structural variants
(SVs). Since these SVs primarily impact noncoding DNA
sequences, the next challenge is one of interpretation, not least
to improve our understanding of human disease etiology.
However, this task is severely complicated by the intricacy of
the gene regulatory landscapes embedded within these noncoding
regions, their incomplete annotation, as well as their dependence
on the three-dimensional (3D) conformation of the genome. Also
in the context of neurodevelopmental disorders (NDDs), reports
of putatively causal, noncoding SVs are accumulating and
understanding their impact on transcriptional regulation is
presenting itself as the next step toward improved genetic
diagnosis.
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INTRODUCTION
Structural variation (SV) represents the greatest source of
genetic diversity in the human genome1–3. Copy-number
variants (CNVs), such as deletions and duplications, as well as
balanced genomic rearrangements, e.g., translocations and
inversions, affect more base pairs than single-nucleotide
variants (SNVs)1–3. CNVs, per definition, result in a gain or
loss of DNA and can therefore affect gene dosage. Balanced
rearrangements on the other hand, although not accompanied
by dosage alterations, can have a significant impact on linear
and 3D chromatin conformation.
Despite their large impact on genome structure, it remains a
challenging task to comprehensively map all SVs in a human
genome. Microarray technology, long the standard in clinical
diagnostics to identify DNA gains and losses, neither allows
the precise mapping of breakpoints, nor the detection of
balanced rearrangements. The advent of next-generation
sequencing technologies has improved SV discovery, although
short-read genome sequencing (GS) approaches have trouble
detecting SVs in repeat-rich regions. Therefore, the most
comprehensive overview of human structural variation to date
has been achieved through a combination of short-read GS
and long-range sequencing technologies, identifying on
average over 27,000 SVs per genome2. For an in-depth
discussion of strategies and algorithms for SV detection we
refer to other reviews4,5.
Given their size (per definition >50 bp), it is unsurprising
that germline SVs can contribute greatly to congenital
disease6. Both de novo and inherited SVs are frequently
linked to the pathogenesis of neurodevelopmental disorders
(NDDs)6–10. NDDs are a heterogeneous group of phenotypes
in which normal development and functioning of the brain is
disrupted, resulting in impairment of motor and behavior
skills, speech, vision, hearing, cognition, etc. They include,
among others, autism spectrum disorder (ASD), intellectual
disability (ID), schizophrenia (SCZ), and developmental delay
(DD). Moreover, these disorders are often syndromic, with
patients also exhibiting a range of other, non-neurological
comorbidities.
It has been estimated that gene dosage alterations caused by
large CNVs are responsible for ~15% of NDD cases11. Apart
from affecting the protein-coding portion of the genome, it
has also been clearly established that SVs can cause disease
through noncoding mechanisms, by altering the copy number
or position of regulatory elements, or by reshuffling higher-
order chromatin structures12. The overall contribution of such
regulatory SV effects in disease etiology is still unclear. Yet,
several experimentally validated examples, in particular in the
context of limb development, have demonstrated their clinical
importance and highlighted the diverse ways in which SVs
can influence gene regulation12. As development of the brain,
the most complex human organ, is tightly regulated, the
impact of noncoding SVs should also be carefully considered
in the context of neurodevelopmental disease. Although the
literature contains multiple examples of noncoding SVs
disrupting loci linked to NDD etiology, a comprehensive
overview of these cases and the underlying, noncoding disease
mechanisms is currently lacking. Therefore, this review aims
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to shed more light on the importance of noncoding SVs in
NDD etiology by discussing (1) the noncoding functional
elements involved in gene regulation during neurodevelop-
ment, (2) the contribution of (noncoding) structural variation
in NDDs, and (3) an extensive collection of reported NDD
cases in which noncoding SVs appear to be at the root of the
NDD phenotype.
GENE REGULATION IN NEURODEVELOPMENT
Development of the human brain is a highly regulated
process in which genes must be switched on in the right place
at the right time. Dynamic, spatiotemporal gene
expression programs orchestrate all stages of neurodevelop-
ment, including neural stem cell proliferation, neuronal
differentiation, and, ultimately, the migration and integration
of postmitotic neurons13. Errors in the regulation of any of
these processes could result in aberrant development and give
rise to NDDs.
The activity of noncoding functional elements regulates
neurodevelopment
The regulatory machinery steering these transcriptional
programs depends on the transcription of noncoding RNA
(ncRNA) molecules, the activity of noncoding regulatory
elements such as enhancers, and the 3D interaction between
these noncoding regulatory sites and protein-coding target
genes (Fig. 1).
Noncoding RNAs
Transcription of noncoding sequences by RNA polymerase II
is widespread in the human genome14. Both the process of
transcription itself, as well as the resulting ncRNA molecules,
can have a regulatory function. Small (21–25 nt) microRNAs
(miRNAs) are primarily associated with gene repression,
among others, via binding to the 3’ untranslated region
(3’UTR) of genes (Fig. 1)15. Several examples highlight their
relevance to NDD etiology. For instance, miR-137 is thought
to perform a regulatory role during neurodevelopment and
has been associated with SCZ and other neuropsychiatric
disorders through genome-wide association studies
(GWAS)16. Also, the overexpression of miRNAs on chromo-
some 21 and ensuing haploinsufficiency of their target genes
is thought to contribute to ID in Down syndrome patients17.
However, the largest and most diverse group of ncRNA
molecules is that of the long noncoding RNAs (lncRNAs).
These are per definition longer than 200 nucleotides and
include transcripts overlapping other genes (sense or
antisense), intergenic transcripts, as well as enhancer RNAs
(eRNAs) transcribed from active enhancer elements18.
LncRNAs perform their regulatory activity via different
mechanisms, both in cis, at the site of transcription, and in
trans. They can influence gene regulation by acting as
scaffolds, mediating the formation and sequence-specific
binding of regulatory protein complexes, or decoys, seques-
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Fig. 1 The gene regulatory landscape from a linear and three-dimensional perspective. (a) Genetic locus, illustrating the regulatory function of
multiple noncoding elements. The region is delimited by topologically associated domain (TAD) boundaries on either side, each consisting of a cluster of
CTCF binding sites. A protein-coding sequence is flanked by a promoter and 5’ and 3’ untranslated region (UTR). An intergenically transcribed long
noncoding RNA (lncRNA) performs its regulatory function by acting as a scaffold for the binding of transcription factors (TFs). The activity of multiple
enhancer elements in the locus is tissue- and even cell-type-dependent. (b) Via a loop extrusion mechanism, anchored by the CTCF-bound TAD boundaries,
the functional elements in the locus are brought into close physical proximity, allowing interaction between the promoter and active enhancers and the
assembly of the transcriptional machinery.
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and miRNAs (Fig. 1)18. However, as regulatory elements
(both promoters and enhancers) initiate bidirectional tran-
scription, it is possible that many antisense lncRNAs and
eRNAs are by-products of this process and do not fulfill
sequence-specific functions19. In these cases, the act of
transcription itself or underlying regulatory element may still
contribute to gene regulation20.
Although the function of many lncRNAs remains elusive
and their functionality in some cases uncertain, several
observations have suggested that they play an important
role during neurodevelopment. Expression profiling by the
GENCODE consortium showed that many lncRNAs are
tissue-specific, with the largest group (~40%) being expressed
specifically in the brain21. There are multiple examples of
lncRNAs fulfilling a specific regulatory function in all stages
of neurodevelopment and in neuronal plasticity18. The Evf2
lncRNA, transcribed from a Dlx5/6 enhancer, recruits the
transcription factors Dlx and Mecp2 to Dlx5/6 enhancer
elements22. Moreover, it also influences chromatin topology
to regulate Dlx5/6 enhancer interactions by binding both
activated and repressed target genes on chromosome 6 and
regulating cohesin positioning23. Pnky is involved in neocor-
tical development by regulating neuronal differentiation24.
Although being transcribed divergently from the Pou3f2
locus, it works via a trans mechanism. Dlx1as and Six3os both
play a role in glial–neuronal lineage specification of neural
stem cells25, while Paupar regulates olfactory bulb neurogen-
esis26. Kleaveland et al. even described a regulatory network in
which a lncRNA (Cyrano), a circular RNA (Cdr1as), and two
miRNAs (miR-7 and miR-671) work together to regulate
neuronal activity27.
As might be expected given their role in neurodevelopment,
lncRNAs have also been implicated in NDDs, among others
through GWAS28. Also, they were found to be enriched in
CNVs identified in ASD patients (Alinejad-Rokny et al.,
unpublished data) and showed differential expression patterns
in blood and brain tissue samples from ASD and major
depressive disorder (MDD) patients29–31. However, it must be
stressed that these disease associations are not conclusive
evidence that the implicated lncRNAs play a role in disease
etiology.
Regulatory elements
Both proximal and distal noncoding regulatory sequences
interact to fine tune protein expression levels. The former
class, found adjacent to the protein-coding gene body,
includes the promoter, which facilitates binding of RNA
polymerase II and initiation of transcription, and the 3’UTR,
harboring miRNA binding sites to mediate gene repression.
Variation in the promoter as well as the 3’UTR of
developmental genes has been linked to NDDs32,33. For
example, several studies leveraged exome sequencing data to
identify noncoding SNVs with a putative regulatory effect in
3’UTRs in patients with ASD, ID, and specific language
impairment34,35.
Yet, the most abundant noncoding regulatory elements
are enhancers, short DNA sequences that can activate gene
expression by recruiting the transcriptional machinery
(sequence-specific TFs, coactivators, and RNA polymerase
II) to a target promoter in a stage- and tissue-specific
manner14. Whether or not enhancers and other regulatory
elements are active in certain tissues or at specific
developmental stages is determined epigenetically, through
DNA methylation and post-translational histone modifica-
tions (reviewed in36,37). Promoters are often regulated by
multiple enhancers, which can display both overlapping and
distinct spatiotemporal activity patterns. While enhancers
with overlapping activities confer a level of redundancy that
ensures a robust transcriptional output resistant to genetic
variation38, those exhibiting differential activities determine
the full spectrum of target gene activity. For example, tissue-
specific enhancers are active in different subregions of the
cerebral cortex, driving precise spatial expression of putative
target genes during cortical development39,40. Song et al.
even demonstrated that 20–40% of active regulatory
elements that interact with the promoters of protein-
coding genes are specific to particular neuronal subtypes,
underlining their importance in cell-type specific
regulation41.
Enhancers can be located exonic, intronic, or intergenic.
They can act upon their target promoter from up to
megabases away, even skipping intervening genes. These
distal enhancers are brought into close physical proximity
with their target promoters via chromatin looping
(Fig. 1)42,43. Enhancer–promoter (E–P) loop formation has
been strongly associated with gene activation during
neurodevelopment. Throughout mouse neural develop-
ment, for example, dynamic E–P interactions are formed
at the time of gene activation and disappear upon gene
repression44. Also during lineage commitment of human
embryonic stem cells into early neural precursors, the
rewiring of E–P contacts happens in conjunction with
changes in chromatin state and target gene expression45.
Although chromatin looping has now been widely accepted
as the predominant mechanism underlying E–P interaction,
recently several cases have been described in which this
mechanism does not apply and E–P distance even increases
upon gene activation, suggesting alternative modes of E–P
communication might be in play46,47.
Variants affecting enhancer elements have been linked to
several NDDs, which are now part of a rapidly expanding
class of what are sometimes collectively termed “enhan-
ceropathies”48. For example, enhancers active during
cortical neurogenesis and in different neural cell types are
enriched for common variants associated with cognitive
function and psychiatric disorders41,49. Moreover, de novo
variants identified in patients with NDDs were also found to
be enriched in regulatory elements, including promoter
regions50 and brain-specific enhancer elements51 (Vas et al.,
unpublished data). For a more detailed discussion on
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enhancer function in brain development and disease we
refer to other reviews52–54.
3D chromatin conformation
As discussed earlier in the context of E–P looping, gene
regulation cannot be interpreted on a linear scale. Indeed,
the human genome is organized into a hierarchical 3D structure
(reviewed in55). On the smallest level E–P loops facilitate
communication between enhancers and their target promo-
ters42,43. E–P interactions are mostly confined to topologically
associated domains (TADs), delimited by CTCF-bound insu-
lator elements (Fig. 1). These insulated domains spatially
constrict interactions, limiting E–P communication across their
boundaries. TADs are thought to be formed through a “loop
extrusion” mechanism, in which cohesin extrudes a chromatin
loop through its ring-shaped structure until it runs into
convergent CTCF-bound sites. At the highest level, compart-
ments group active (A compartments) or inactive (B compart-
ments) TADs. TADs switch compartments (i.e., compartment
switching) when they become activated or repressed, for
example during differentiation56.
The functional importance of this organization during
neurodevelopment is highlighted by two studies demonstrat-
ing a massive rewiring of 3D genomic structures during
mouse44 and human57 neural differentiation, including
changes in compartmentalization, an increase in TAD size
and interaction strength and the formation (or pruning) of
dynamic chromatin loops. Rajarajan et al. found that these
dynamic interactions also include SCZ-associated
sequences57. There is indeed ample evidence that such
structural changes play a role in the etiology of NDDs. For
example, variants affecting the architectural proteins CTCF,
YY1, and STAG1 (a cohesin subunit) were found to cause
ID58–60, while the multisystem disorder Cornelia de Lange
syndrome is frequently associated with variants in the cohesin
loading factor NIPBL and the cohesin subunits SMC1A and
SMC361.
Accessible tools for interpreting variation in the noncoding
genome
The past decade, several consortia have made considerable
efforts to comprehensively map (ncRNA) expression, regula-
tory elements, as well as 3D genomic interactions, across a
variety of cell types, tissues, and developmental stages. These
large data sets are typically easily accessible through dedicated
websites or genome browsers and consulting them should
always be considered as a first step in assessing the functional
consequence of noncoding variants (Table 1). For example,
Middelkamp et al. devised a computational pipeline, based on
a combination of phenotype association and publicly available
chromatin organization data, to predict driver genes that were
directly or indirectly affected by SVs in patients with multiple
congenital anomalies and ID62. However, many functional
elements remain to be discovered and/or have not been
experimentally validated. These lacunae in the functional
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experimental validation, complicate the interpretation of
noncoding variation. Therefore, additional functional assays
might be required to fill the gaps. Recently, experimental
strategies to identify and validate regulatory elements were
extensively reviewed by Gasperini et al.63.
STRUCTURAL VARIATION IN NEURODEVELOP-
MENTAL DISORDERS
The genetic etiology underlying NDDs is heterogeneous,
ranging from large chromosomal aberrations (SVs) to SNVs,
affecting hundreds of genes64. Variants that have arisen de
novo account for the majority of cases65. For example, ~60% of
severe ID cases can be explained by de novo variants (both
SNVs and SVs) in known ID genes66. However, rare inherited
variation has also been shown to contribute to the pathogen-
esis of NDDs. Inherited SVs contribute in almost 4% of ASD
cases9. In addition to these rare de novo and inherited variants,
even common variants add to disease predisposition67.
Noncoding regulatory SVs are enriched in NDDs
As labs are shifting to GS, there has been a tremendous
increase in the identification of variants within noncoding
DNA sequences, both in healthy and diseased individuals. For
example, only ~0.5% of SNVs identified through GS lie within
coding exons1. Interpreting the functional effect of these
noncoding variants represents an enormous challenge. Most
noncoding SNVs and even small indels, unless they disrupt a
crucial functional site (e.g., TF binding site [TFBS]), have a low
probability of affecting the function of regulatory elements.
Indeed, it has been estimated that only 0.15% of possible SNVs
in active brain enhancers could cause NDDs51. Even so, it is
estimated that de novo SNVs in putative regulatory elements
could explain up to 5% of NDD cases6,51,68.
SVs affecting noncoding regions, on the other hand, remove
or multiply kilobases of DNA sequence or even relocate entire
sections of chromosomes and are therefore more likely than
SNVs to have a biologically meaningful impact on gene
regulation. Redin et al. demonstrated that 7% of balanced
translocations in NDDs cause the disruption of TADs69. Also,
SVs affecting regulatory elements seem to be depleted in the
normal population, underscoring their potential to be
deleterious9,70. Brandler et al. showed SV depletion in cis-
regulatory elements (transcription start sites [TSSs], 3’UTRs,
and fetal brain promoters) of loss-of-function intolerant
genes9, while Han et al. found SVs, especially those disrupting
CTCF sites, to occur at significantly lower frequencies than
intergenic SVs70.
Others have demonstrated a direct link between noncoding
SVs and neurodevelopmental disease. De novo CNVs
encompassing human accelerated regions with regulatory
activity are implicated in up to 1.8% of ASD cases71. Also in
the context of ASD, Turner et al. found a slight excess of de
novo CNVs in putative regulatory elements within the vicinity
of ASD genes, although this was not statistically significant
due to a limited sample size10. Similarly, Monlong et al.
detected an enrichment of noncoding CNVs near known
epilepsy genes72, while Brandler et al. showed an enrichment
of paternally inherited regulatory SVs in ASD cases9. Within
the latter ASD cohort no de novo regulatory SVs were
identified, illustrating another mode of NDD etiology and
underscoring that screening of larger NDD cohorts will be
required to uncover the full spectrum of noncoding SVs
underlying NDDs.
Functional consequence of noncoding SVs
The pathogenicity of SVs affecting protein-coding genes can
in most cases be explained, quite intuitively, by gene dosage
effects. However, the effect of noncoding aberrations on gene
expression is more difficult to predict. Still, it has been shown
that noncoding SVs alter the expression of nearby genes with
larger effect sizes than noncoding SNVs or indels73. More-
over, the expression of target genes is negatively correlated
with the total sum of enhancer sequence affected by an SV
(both for deletions and duplications)70. Both observations
demonstrate a link between the number of affected nucleo-
tides and the magnitude of the functional effect.
There are several extensively studied cases that have given
insight into the different mechanisms through which non-
coding SVs can impact gene regulation, 3D chromatin
structure, and, eventually, influence gene expression and
phenotypic outcome (reviewed in detail in12,43). These include
both dosage and positional effects (i.e., they can change either
the copy number or order of regulatory elements). CNVs that
delete, duplicate, or amplify noncoding sequences potentially
alter the dosage of ncRNA genes or regulatory elements, in
turn affecting the expression of target genes. However, this
effect on target gene expression might be difficult to predict.
As gene expression is often the result of the combinatorial
action of multiple enhancer elements with (partly) over-
lapping activity patterns, the degree of enhancer redundancy
will influence the functional consequences. For example, the
individual deletion of ten different enhancer elements at loci
involved in limb development did not result in a limb
phenotype, while the deletion of pairs of enhancers did38.
SVs that span TAD boundaries can, in addition to causing
dosage effects, also influence 3D chromatin structure. The
deletion of a TAD boundary facilitates the fusion of
adjacent TADs, while a duplication involving a TAD
boundary can result in the creation of a new chromatin
domain or neo-TAD. Inversions and translocations reshuf-
fle the TAD structure by repositioning boundaries. These
alterations in the 3D chromatin structure can bring about
the decoupling of a promoter from its cognate enhancers
resulting in a regulatory loss of function, while at the same
time the adoption of new enhancers with different
spatiotemporal activities might lead to ectopic gene activa-
tion74. However, these mechanisms are not necessarily
generalizable. For some loci the removal of TAD boundaries
and ensuing TAD fusion does not appear to result in gene
expression changes75.
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SVS IMPACTING GENE REGULATION IN NDDS:
SPECIFIC CASES
Because of the complexity of the gene regulatory landscape
illustrated above, the medical interpretation of SVs in
noncoding regions requires a case-by-case evaluation of the
functional impact on gene expression and phenotypic
outcome. To better understand the diverse ways in which
noncoding SVs contribute to the etiology of NDDs, we have
compiled an extensive list of loci harboring putatively causal,
noncoding SVs in patients with NDDs (Table 2).
lncRNAs disrupted by SVs in NDDs
Although differential expression of lncRNAs has frequently
been linked to NDDs29–31, it is often difficult to disentangle
association from causation. Cases in which disruption of a
specific lncRNA gene appears to be the causal disease
mechanism are still limited in number and come with a
varying degree of functional evidence. Therefore, it remains
unsure whether this is a widespread phenomenon in the
etiology of NDDs and disease in general.
By 1996, chromosomal aberrations affecting the lncRNA
gene DGCR5 had been identified in patients with DiGeorge
syndrome76. More recently, CNVs situated within the same
22q11.2 critical region were found to be associated with SCZ
as well7. Although this region also harbors several protein-
coding genes, based on coexpression analysis using brain
transcriptome data from the PsychENCODE project, DGCR5
was identified as a hub regulator77. Moreover, DGCR5
knockdown and overexpression in induced pluripotent stem
cell (iPSC)–derived human neural progenitors demonstrated
that this lncRNA regulates the expression of several SCZ-
associated genes77.
Very recently, differential expression analysis during
mouse neuronal induction implicated the highly conserved
lnc-NR2F1, transcribed divergently from the NR2F1 locus,
in neurodevelopment78. Overlap of this lncRNA with a focal
deletion found in ASD/ID patients and a newly identified,
paternally inherited translocation confirmed its clinical
relevance in NDD etiology (Fig. 2a). Both gain- and loss-of-
function experiments in mouse have demonstrated that lnc-
Table 2 Examples of noncoding structural variants (SVs) putatively causal in neurodevelopmental disorders (NDDs).
Locus Affected
genea
SV type Noncoding disease mechanism NDD phenotype Reference
lncRNAs
22q11.2 DGCR5 Translocation, deletion DGCR5 haploinsufficiency DiGeorge syndrome; SCZ 76,77
5q15 lnc-NR2F1 Translocation, deletion lnc-NR2F1 haploinsufficiency DD, facial dysmorphisms, hearing loss 78
Xp22.11 PTCHD1-AS Deletion PTCHD1-AS haploinsufficiency ASD 79
14q21.1 lncLRFN5-
10
Deletion LRFN5 haploinsufficiency ASD 80
2p25.1 LINC00299 Translocation, deletion LINC00299 haploinsufficiency DD, ID 81,82
12q23.1 RMST Translocation RMST haploinsufficiency Kallmann syndrome 85
14q32.2 MEG3 Deletion (maternal) MEG haploinsufficiency upd(14)pat phenotype 86
15q11-13 SNORD116 Deletion snoRNA haploinsufficiency Prader–Willi syndrome 87,88
Near cis-regulatory elements (promoter and 5’&3’ UTR)
Xq27.3 FMR1 CGG repeat expansion Promoter hypermethylation Fragile X syndrome 90
16p12.3 XYLT1 GGC repeat expansion Exon 1 hypermethylation Baratela–Scott syndrome 92
Xq28 AFF2 CCG repeat expansion Promoter hypermethylation ID 90
2q11.2 AFF3 CGG repeat expansion Promoter hypermethylation ID 90
12q13.1 DIP2B CGG repeat expansion Promoter hypermethylation ID 90
16q21 GPR56 Deletion Promoter TFBS disruption Polymicrogyria, ID, speech delay,
seizures
52
Intergenic regulatory elements and 3D chromatin conformation
7q36.3 SHH Translocation Enhancer displacement Holoprosencephaly 93
14q12 FOXG1 Translocation, deletion Enhancer displacement/removal or 3D
reorganization
Congenital Rett syndrome 69,97
5q14.3 MEF2C Translocation, deletion,
inversion
Enhancer displacement/removal Rett-like syndrome 69,98
2q33.1 SATB2 Translocation, inversion Enhancer displacement Glass syndrome 69,100




Pierre Robin sequence Cooks
syndrome, sex reversal
101,102
Xq27.1 SOX3 Insertion, deletion Enhancer insertion/removal Variable phenotypes 62,104,105
7q21.3 DLX5/6 Translocation, deletion,
inversion
Enhancer displacement/removal SHFM1, ID, craniofacial defects,
hearing loss
107,108
4q25 PITX2 Translocation, deletion Enhancer displacement/removal Rieger syndrome 69,111,112
11p13 PAX6 Translocation Enhancer displacement Aniridia 52,113
Xp21.3 ARX Duplication Enhancer duplication ID, epilepsy, lissencephaly 52
6p24.3 TFAP2A Translocation, inversion Enhancer displacement, 3D
reorganization
BOFS 114
14q32.2 BCL11B Translocation Enhancer removal DD, speech delay, ID 115
1p34.2 SLC2A1 Translocation Enhancer displacement Epilepsy, DD 69
7q36.3 VIPR2 Duplication Unknown SCZ 52
15q26.2 NR2F2 Duplication Enhancer duplication ASD, ID 71
21q22.2 DSCAM Intronic deletion Enhancer removal ASD 10
2p12 CTNNA2 Translocation Enhancer displacement ID, DD 116
ASD autism spectrum disorder, BOFS branchiooculofacial syndrome, DD developmental delay, ID intellectual disability, SCZ schizophrenia, SHFM1 split hand/foot mal-
formation 1, TF transcription factor, TFBS TF binding site.
aDirectly or indirectly.
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Nr2f1 promotes neuronal maturation pathways in a
functionally distinct fashion from its neighboring gene
Nr2f1, while chromatin association assays showed that it
binds to neuronal targets in trans to exert that function78.
Also in the context of ASD, PTCHD1-AS was found to be
frequently affected by microdeletions in male patients79.
This lncRNA lies upstream of the PTCHD1 gene, which is a
transmembrane protein known to be involved in NDDs.
iPSC-derived neurons of patients with PTCHD1-AS dele-
tions showed decreased excitatory synaptic activity,
although PTCHD1 expression does not appear to be
affected. This in contrast to lncLRFN5-10, which does
appear to regulate expression of its nearby gene LRFN5 and
was also found to be affected by a microdeletion in an ASD
patient80. Translocations and deletions disrupting
LINC00299 have been identified in patients with DD and
ID81,82. Although it has been demonstrated that LINC00299
expression increases during neural differentiation, its
precise function is still unknown.
RMST was also first associated with neurodevelopment
through transcriptomic analyses. This lncRNA was found to
be upregulated during neuronal differentiation and was
shown to regulate this process through interaction with the
SOX2 TF83,84. Recently, a de novo balanced translocation
disrupting RMST was identified in a patient with Kallmann
syndrome, a disorder caused by deficient development of
gonadotropin-releasing hormone (GnRH) neurons and fea-
tured by abnormal sexual development and an impaired sense
of smell (Fig. 2b)85. The translocation caused a reduction in
RMST expression in patient neural crest cells (NCCs), the
cells from which GnRH neurons originate, resulting in
abnormal NCC morphological development85.
The dysregulation of lncRNAs within imprinted regions has
also been associated with NDDs. For instance, microdeletions
involving the differentially methylated regions (DMRs) of
maternal origin upstream of the maternally expressed gene 3
(MEG3) lncRNA result in a loss of MEG expression and a
phenotype resembling that of paternal uniparental disomy 14
(upd[14]pat) patients (growth retardation, DD, facial
abnormalities, small bell-shaped thorax, abdominal defects,
and polyhydramnios) (Fig. 2c)86. Finally, the deletion of the
imprinted SNORD116 noncoding gene cluster on the paternal
allele results in Prader–Willi syndrome (PWS) (Fig. 2d)87,88.
SNORD116 is processed into 30 small nucleolar RNAs
(snoRNAs). The production of these snoRNAs appears to
be neurospecific89 and their deletion results in smaller
neuronal cell bodies due to a decrease in nucleolar size88.
However, the precise role of these snoRNAs in the nucleolus
remains unsolved.
Disruption of near cis-regulatory elements (promoter, 5’ &
3’ UTR) in NDDs
As near cis-regulatory elements, such as the promoter and 5’
and 3’ UTR, are typically small in size and directly flanking
the coding sequence, they are inherently less likely to be
affected by SVs that leave the protein-coding gene body intact.
However, there are a few examples of larger genomic variants
disrupting these near-cis sequences in the context of NDDs.
Undoubtedly one of the most well-known examples is the
CGG repeat expansion in the 5’ UTR of the FMR1 gene,
resulting in DNA hypermethylation at the promoter, silencing
FMR1 and giving rise to fragile X syndrome90. Interestingly,
this repeat expansion also disrupts the TAD boundary
adjacent to FMR1, decoupling FMR1 from putative down-
stream enhancers91. As the extent of the disruption correlates
to FMR1 silencing, it is possible that part of the FMR1 loss is
attributable to this 3D rearrangement. Repeat expansions in
near cis-regulatory elements are a recurrent cause of NDDs. A
GGC repeat expansion in the XYLT1 promoter of patients
with Baratela–Scott syndrome results in hypermethylation of
the first exon and reduced XYLT1 expression92. Repeat
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Fig. 2 Structural variants disrupt noncoding RNA genes in patients with neurodevelopmental disorders (NDDs). Illustration of NDD cases in
which the disruption of a noncoding RNA locus has been identified as the causal mechanism (four examples, a–d). (Noncoding) genes are depicted as blue
and gray boxes, red bars are patient deletions, arrows are translocation breakpoints. The epigenetically regulated MEG3 differentially methylated regions
(DMRs) and Prader–Willi imprinting control (IC) region are represented by orange boxes.
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FRAXE (5’ UTR of AFF2), FRA2A (promoter of AFF3), and
FRA12A (5’ UTR of DIP2B)90.
Other types of SVs have also been reported within near cis-
regulatory sequences. For example, a deletion in the promoter
region of GPR56, disrupting an RFX TFBS, leads to gyral
malformations in a specific region of the cortex, resulting in
speech delay, ID, and seizures52. Variants affecting the coding
sequence of GPR56 typically result in polymicrogyria of the
entire cortex. However, as the regulatory deletion is located
within the promoter of only one of multiple alternative TSSs,
it only eliminates GPR56 expression in the lateral neocortex,
explaining the regionally restricted phenotype.
SVs disrupt long-range gene regulation and 3D chromatin
structure in NDDs
Most noncoding SVs associated with NDDs are situated
within the large stretches of intergenic space, affecting
regulatory interactions between promoters and enhancers
and/or altering the 3D chromatin conformation of the locus
(see section above). Variants affecting the ZRS limb enhancer
at the SHH locus are well known to cause limb malformations.
However, translocations upstream of SHH, disrupting the
interaction between the SHH promoter and SHH brain
enhancers (SBE6, SBE4, SBE2, and SBE3), have been
identified as a cause of holoprosencephaly (Fig. 3a)93,94.
The FOXG1 TF has been associated with a congenital form
of Rett syndrome, an NDD featured by severe DD, absence of
speech, seizures, hypotonia, and stereotypic movements. The
gene is located in a large, gene-poor TAD with a pronounced
sub-TAD structure and multiple interaction loops, bringing
the promoter into the proximity of several in vivo validated
brain enhancers95,96. This regulatory structure is disrupted by
translocations and deletions distal to FOXG1 in multiple
patients with similar Rett-like features (Fig. 3b), likely caused
by either enhancer deletion/translocation or a rewiring of
interactions due to the deletion of TAD boundary ele-
ments69,97. SVs in the 5q14.3 region upstream of MEF2C
result in a Rett-like syndrome as well (Fig. 3c)69,98. This
upstream region harbors multiple enhancer elements that
display in vivo neuronal activity during zebrafish develop-
ment and form a physical interaction network with the
MEF2C promoter in neuronal cells, suggesting that MEF2C
transcriptional dysregulation by enhancer deletion or trans-
location lies at the root of the MEF2C-related phenotype98.
Loss-of-function variants in SATB2 or microdeletions in the
2q33.1 region affecting SATB2, typically give rise to SATB2-
associated syndrome, an NDD characterized by ID and
dysmorphic facial features99. Six patients with BCA break-
points in the gene desert 3’ to SATB2 exhibited overlapping
clinical features (Fig. 3d)69,100. Each of these breakpoints
disrupts the long-range interactions between SATB2 and
multiple putative enhancer elements, of which at least one
(CRE2) drives SATB2-like craniofacial expression in zebra-
fish100. Interestingly, the activity of this element appears to be
dependent on binding of the SOX9 TF, which has been
associated with a craniofacial disorder with overlapping
clinical features called Pierre Robin sequence (PRS), suggest-
ing that SATB2 regulation might be primarily driven by
SOX9. Translocations and microdeletions upstream of SOX9
have also been identified in patients with PRS, while
duplications involving the TAD boundary give rise to Cooks
syndrome and intra-TAD duplications cause sex reversal
(Fig. 3e)101,102. The effects of these SVs on gene regulation
and 3D conformation at the SOX9 locus have been discussed
at length by others12,103. Duplications and deletions of the
SOX3 TF cause ID and growth hormone deficiency.
Intriguingly, multiple SVs have been identified in the gene
desert surrounding SOX3 in patients with varying phenotypes
without ID (Fig. 3f). A region 82 kb downstream of the gene is
especially prone to insertions due to the presence of a human-
specific short palindromic sequence. The distinct symptoms
observed in these patients suggest the phenotypes might be
caused by the introduction of tissue-specific enhancer
elements driving ectopic SOX3 expression. A 170-kb fragment
from chromosome 9 was inserted at this site in a patient with
cleft palate and facial dysmorphism62. The insertion con-
tained part of a superenhancer region with craniofacial
activity, possibly altering SOX3 expression during craniofacial
development and resulting in the patient’s phenotype.
Insertions of other genomic fragments resulted in a severe
hair overgrowth phenotype (hypertrichosis), drooping eyelids
(ptosis), XX male sex reversal, and X-linked recessive
hypoparathyroidism104,105. Additionally, an upstream micro-
deletion was identified in a patient with XX male sex
reversal106.
Chromosomal aberrations affecting the DLX5/6 locus cause
split hand/foot malformation 1 (SHFM1), often combined
with ID, craniofacial defects, and hearing loss. Several of these
SVs have breakpoints upstream of DLX5/6 and disrupt
multiple tissue-specific enhancer elements, which regulate
DLX5/6 expression in the forebrain, branchial arch, ear, and
limb (Fig. 3g)107,108. Patients can even be classified into three
phenotypic groups, correlating with the deletion of specific
enhancer elements107–109. Variants disrupting the PITX2 TF
are typically associated with Rieger syndrome, a develop-
mental disorder characterized by ocular and craniofacial
anomalies, with some patients also displaying neurological
deficits110. Translocations and deletions affecting conserved
enhancer elements (with brain, eye, and craniofacial activity)
in the gene desert upstream of PITX2 result in a similar
phenotype (Fig. 3h)69,111,112. Variants in the coding sequence
of PAX6 give rise to the congenital eye malformation aniridia,
as well as neurodevelopmental defects. Translocations in the
downstream regulatory region were found to result in a
similar phenotype52,113.
While many of these examples consist of deletions or
translocations, duplications of noncoding sequences have also
been associated with NDDs. Coding variants or small
duplications in the ARX TF are a frequent cause of X-
linked ID, epilepsy, and lissencephaly. Its specific expression
in different regions of the forebrain is tightly controlled by
ultraconserved enhancers downstream of the coding
D’HAENE and VERGULT REVIEW ARTICLE
























Fig. 3 Noncoding structural variants disrupt gene regulation and 3D chromatin structure in neurodevelopmental disorders (NDDs). Illustration
of NDD cases in which the disruption of regulatory elements and/or 3D chromatin conformation has been identified as the causal mechanism (ten examples,
a–j). Blue triangles reflect the topologically associated domain (TAD) structure of the locus. Depicted are (noncoding) genes represented by blue (gene of
interest) and gray (other gene) boxes, brain enhancer elements (green ovals), patient deletions (red bars), duplications (purple bars), insertions (red triangles),
and translocation or inversion breakpoints (red arrows).
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sequence, with partially overlapping spatial activity patterns39.
Duplications encompassing these ARX forebrain enhancers
cause a similar, although milder, phenotype (Fig. 3i)52.
Also in patients with complex genomic rearrangements
noncoding SVs can contribute to the overall phenotype. For
example, Middelkamp et al. identified four candidate driver
genes (i.e., PHIP, COL12A1, BMP2, and TFAP2) in a patient
with a complex rearrangement consisting of six breakpoint
junctions and two deletions on three different chromo-
somes62. Each of the driver genes individually can only
account for part of the phenotype (i.e., DD, autism, seizures,
facial dysmorphism, growth delay, missing ribs, renal
agenesis, and cryptorchidism), yet together they might explain
the full phenotypic spectrum. PHIP and COL12A1 were
directly affected by a deletion and have been associated with
DD and facial dysmorphisms. In addition, BMP2 and
TFAP2A appeared to be affected by a disruption of long-
range interactions. Several breakpoints were identified
upstream of BMP2, linked to short stature, facial dysmorph-
isms, and skeletal anomalies, and also the TFAP2A TAD was
disrupted by a translocation. Recently, a de novo heterozygous
inversion disrupting the TFAP2A TAD was also identified in a
patient with branchiooculofacial syndrome (BOFS; branchial
cleft, ocular anomalies, facial dysmorphisms) (Fig. 3j)114. The
TFAP2A TF regulates neural crest development and its
expression in NCCs is controlled by multiple enhancers.
Laugsch et al. have demonstrated that the inversion separates
TFAP2A from its NCC enhancers, leading to monoallelic
expression and TFAP2A haploinsufficiency. Interestingly, no
enhancer adoption occurs in this case, even though the
inversion places these relocated enhancers within the spatial
proximity of other genes.
Finally, in some cases functional evidence for a noncoding
disease mechanism is still limited. For example, translocations
3’ to the BCL11B TF gene were found in patients with DD,
speech impairment, and ID115. Expression was reduced by
50% in patient cells, suggesting BCL11B haploinsufficiency
due to relocation of regulatory elements. Redin et al. identified
a patient, displaying epilepsy and DD, with a translocation
affecting the SLC2A1 TAD and decreasing SLC2A1 expres-
sion in patient cells69. The translocation disrupts the
interaction between SLC2A1, a gene associated with the
seizure disorder GLUT1 deficiency syndrome, and several
putative enhancer elements. Duplications of the 7q36 region,
either including or just upstream of VIPR2, result in
upregulation of VIPR2 and cause schizophrenia in patients52.
Interestingly, it seems like the overexpression pattern cannot
only be explained by an increase in gene dosage, suggesting
that these duplications affect VIPR2 regulation as well. A de
novo duplication 300 kb upstream of NR2F2, a gene
associated with ASD and ID, duplicates a human accelerated
region that has been shown to interact with the NR2F2
promoter, possibly exerting a regulatory function during
neural development71. Intronic CNVs can also affect gene
regulation. A 14-kb inherited, intronic deletion in the DSCAM
gene has been identified in an autism patient10. The deletion
removes at least nine enhancer elements driving expression in
the central nervous system (CNS). Recently, Melo et al.
identified a translocation disrupting the CTNNA2 TAD in a
patient with ID and DD116. Although homozygous variants in
this gene cause cortical dysplasia and other brain malforma-
tions, a noncoding disease mechanism has not yet been
investigated. Furthermore, putatively disease-causing SVs
have been found disrupting the noncoding regions surround-
ing RAP1A (Kabuki syndrome), PPP3CA (epilepsy and ID),
RAC1 (ID), PAFAH1B1 (lissencephaly), ALX4
(Potocki–Shaffer syndrome), FOXP2 (speech and language
disorder), and TGFB2 (~ID)62,117.
CONCLUSION AND PERSPECTIVES
The cases discussed above clearly demonstrate the importance
of considering noncoding effects when interpreting SVs in the
context of NDDs. Studying these cases and experimentally
investigating gene regulation within these loci could greatly
improve our understanding of the noncoding disease
mechanisms at play, ultimately benefiting the medical
interpretation of structural variation. For many, however,
the underlying noncoding disease mechanism has not yet
been fully resolved. This is especially true for the SVs
putatively disturbing long-range gene regulation and/or 3D
chromatin structure. In many of these cases a disruption of
communication between the promoter and its cognate
enhancer sequences, either due to enhancer deletion or
relocation, is thought to be the causal mechanism. However,
(part of) the effect may also be caused by the acquisition of
new interactions as a result of TAD fusion or reshuffling.
Further experimental validation will be needed to ascertain
how these different mechanisms contribute to the disease
phenotype.
There are some loci for which the effect of noncoding SVs
has been extensively studied, especially in the context of limb
malformations12. These studies have demonstrated that the
effects are locus-dependent and are therefore difficult to
predict. This clearly exemplifies the complexity of the gene
regulatory landscape and our imperfect understanding of the
role, determinants, and necessity of the 3D chromatin
structure. Also hampering the functional assessment of
structural variation is the incomplete annotation of the
noncoding genome on a tissue-specific level. Although several
large studies have predicted the presence of functional
elements throughout the genome for a variety of tissues and
cell types, these predictions are based on biochemical
properties (e.g., TF binding, open chromatin, histone
modifications) and do not guarantee that these sequences
perform a regulatory function in vivo. As a result, most of
these putative functional elements still require experimental
validation, be it via high-throughput screening assays (e.g.,
ChIP/ATAC-STARR-seq118,119 or CRISPR(i) screening120) or
in focused studies.
A more complete annotation of the noncoding genome and
a better understanding of different noncoding disease
mechanisms will also improve our ability to predict the
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transcriptional and phenotypic consequences of newly
identified, noncoding SVs. This is not only true for the large
de novo SVs discussed here, but also for (combinations of)
inherited variants with smaller individual effects. Moreover,
while this review focused on structural variation, an enormous
challenge is looming ahead to interpret the millions of
noncoding SNVs identified in patient genomes as well. In
contrast to the relatively large SVs, most of these single-
nucleotide changes are likely to have no (or very small)
functional effect(s), rendering the prediction of variant effects,
prioritization, and validation possibly even more crucial.
A multiomics approach has been proposed to unify variant
detection and interpretation, by combining information on a
genomic, epigenomic, transcriptomic, and even functional
genomic level121. This could be achieved, for example, by
simultaneously implementing GS for variant identification,
Hi-C analysis of 3D chromatin structure, RNA-seq profiling
of transcriptional activity, and high-throughput assays for the
functional validation of putative regulatory elements. Such an
approach should ultimately aid in closing the gap in the
genetic diagnosis of NDD patients, while at the same time
improving our understanding of gene regulatory mechanisms.
ACKNOWLEDGEMENTS
This work was supported by the Research Foundation Flanders
(FWO) under grant G044615N and 1520518N. In addition, E.D. is
also supported by a doctoral fellowship of the FWO Research
Fund and was previously supported by a fellowship of the
Marguerite-Marie Delacroix Fund. We thank our colleagues Björn
Menten, Annelies Dheedene, and Griet De Clercq for their
valuable feedback on the manuscript.
DISCLOSURE
The authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional
affiliations.
REFERENCES
1. The 1000 Genomes Project Consortium. A global reference for human
genetic variation. Nature. 2015;526:68–74.
2. Chaisson MJP, et al. Multi-platform discovery of haplotype-resolved
structural variation in human genomes. Nat Commun. 2019;10:1784.
3. Collins RL, et al. A structural variation reference for medical and
population genetics. Nature. 2020;581:444–451.
4. Ho SS, Urban AE, Mills RE. Structural variation in the sequencing era. Nat
Rev Genet. 2020;21:171–189.
5. De Coster W, Van Broeckhoven C. Newest methods for detecting
structural variations. Trends Biotechnol. 2019;37:973–982.
6. Wilfert AB, Sulovari A, Turner TN, Coe BP, Eichler EE. Recurrent de novo
mutations in neurodevelopmental disorders: properties and clinical
implications. Genome Med. 2017;9:101.
7. Marshall CR, et al. Contribution of copy number variants to schizophrenia
from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49:
27–35.
8. Coe BP, et al. Refining analyses of copy number variation identifies
specific genes associated with developmental delay. Nat Genet.
2014;46:1063–1071.
9. Brandler WM, et al. Paternally inherited cis-regulatory structural variants
are associated with autism. Science. 2018;360:327–331.
10. Turner TN, et al. Genome sequencing of autism-affected families reveals
disruption of putative noncoding regulatory DNA. Am J Hum Genet.
2016;98:58–74.
11. Kaminsky EB, et al. An evidence-based approach to establish the
functional and clinical significance of copy number variants in intellectual
and developmental disabilities. Genet Med. 2011;13:777–784.
12. Spielmann M, Lupiáñez DG, Mundlos S. Structural variation in the 3D
genome. Nat Rev Genet. 2018;19:453–467.
13. Nord AS, Pattabiraman K, Visel A, Rubenstein JLR. Genomic perspectives
of transcriptional regulation in forebrain development. Neuron.
2015;85:27–47.
14. ENCODE. An integrated encyclopedia of DNA elements in the human
genome. Nature. 2012;489:57–74.
15. Iwakawa H, oki, Tomari Y. The functions of microRNAs: mRNA decay and
translational repression. Trends Cell Biol. 2015;25:651–665.
16. Mahmoudi E, Cairns MJ. MiR-137: An important player in neural
development and neoplastic transformation. Mol Psychiatry. 2017;22:44–55.
17. Elton TS, Sansom SE, Martin MM. Trisomy-21 gene dosage over-
expression of miRNAs results in the haploinsufficiency of specific target
proteins. RNA Biol. 2010;7:540–547.
18. Briggs JA, Wolvetang EJ, Mattick JS, Rinn JL, Barry G. Mechanisms of long
noncoding RNAs in mammalian nervous system development, plasticity,
disease, and evolution. Neuron. 2015;88:861–877.
19. Li W, Notani D, Rosenfeld MG. Enhancers as noncoding RNA
transcription units: recent insights and future perspectives. Nat Rev
Genet. 2016;17:207–223.
20. Engreitz JM, et al. Local regulation of gene expression by lncRNA
promoters, transcription and splicing. Nature. 2016;539:452–455.
21. Derrien T, et al. The GENCODE v7 catalog of human long noncoding
RNAs: analysis of their gene structure, evolution, and expression.
Genome Res. 2012;22:1775–1789.
22. Bond AM, et al. Balanced gene regulation by an embryonic brain ncRNA
is critical for adult hippocampal GABA circuitry. Nat Neurosci.
2009;12:1020–1027.
23. Cajigas I, et al. The Evf2 ultraconserved enhancer lncRNA functionally and
spatially organizes megabase distant genes in the developing forebrain.
Mol Cell. 2018;71:956–972.e9.
24. Andersen RE, et al. The long noncoding RNA Pnky is a trans-acting
regulator of cortical development In vivo. Dev Cell. 2019;49:632–642.e7.
25. Ramos AD, et al. Integration of genome-wide approaches identifies
lncRNAs of adult neural stem cells and their progeny in vivo. Cell Stem
Cell. 2013;12:616–628.
26. Pavlaki I. et al. The long non‐coding RNA Paupar promotes KAP 1‐
dependent chromatin changes and regulates olfactory bulb
neurogenesis. EMBO J. 2018;37:e98219.
27. Kleaveland B, Shi CY, Stefano J, Bartel DP. A network of noncoding
regulatory RNAs acts in the mammalian brain. Cell. 2018;174:350–362.
e17.
28. D’haene E, et al. Identification of long noncoding RNAs involved in
neuronal development and intellectual disability. Sci Rep. 2016;6:28396.
29. Ziats MN, Rennert OM. Aberrant expression of long noncoding RNAs in
autistic brain. J Mol Neurosci. 2013;49:589–593.
30. Wang Y, et al. Genome-wide differential expression of synaptic long
noncoding RNAs in autism spectrum disorder. Transl Psychiatry. 2015;5:
e660.
31. Liu Z, et al. Microarray profiling and co-expression network analysis of
circulating lncRNAs and mRNAs associated with major depressive
disorder. PLoS One. 2014;9:e93388.
32. Zhang L, et al. A promoter variant in ZNF804A decreasing its expression
increases the risk of autism spectrum disorder in the Han Chinese
population. Transl Psychiatry. 2019;9:31.
33. Coutinho AM, et al. MECP2 coding sequence and 3′UTR variation in 172
unrelated autistic patients. Am J Med Genet B. 2007;144B:475–483.
34. Devanna P, et al. Next-gen sequencing identifies noncoding variation
disrupting miRNA-binding sites in neurological disorders. Mol Psychiatry.
2018;23:1375–1384.
35. Devanna P, van de Vorst M, Pfundt R, Gilissen C, Vernes SC. Genome-
wide investigation of an ID cohort reveals de novo 3′UTR variants
affecting gene expression. Hum Genet. 2018;137:717–721.
36. Bannister AJ, Kouzarides T. Regulation of chromatin by histone
modifications. Cell Res. 2011;21:381–395.
37. Greenberg MVC, Bourc’his D. The diverse roles of DNA methylation in
mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20:
590–607.
REVIEW ARTICLE D’HAENE and VERGULT
44 Volume 23 | Number 1 | January 2021 | GENETICS in MEDICINE
38. Osterwalder M, et al. Enhancer redundancy provides phenotypic
robustness in mammalian development. Nature. 2018;554:239–243.
39. Visel A, et al. A high-resolution enhancer atlas of the developing
telencephalon. Cell. 2013;152:895–908.
40. Pattabiraman K, et al. Transcriptional regulation of enhancers active in
protodomains of the developing cerebral cortex. Neuron. 2014;82:
989–1003.
41. Song M, et al. Mapping cis-regulatory chromatin contacts in neural cells
links neuropsychiatric disorder risk variants to target genes. Nat Genet.
2019;51:1252–1262.
42. Schoenfelder S, Fraser P. Long-range enhancer–promoter contacts in
gene expression control. Nat Rev Genet. 2019;20:437–455.
43. Robson MI, Ringel AR, Mundlos S. Regulatory landscaping: how
enhancer-promoter communication is sculpted in 3D. Mol Cell.
2019;74:1110–1122.
44. Bonev B, et al. Multiscale 3D genome rewiring during mouse neural
development. Cell. 2017;171:557–572.e24.
45. Freire–Pritchett P, et al. Global reorganisation of cis-regulatory units upon
lineage commitment of human embryonic stem cells. eLife. 2017;6:
e21926.
46. Benabdallah NS, et al. Decreased enhancer-promoter proximity
accompanying enhancer activation. Mol Cell. 2019;76:473–484.e7.
47. Alexander JM, et al. Live-cell imaging reveals enhancer-dependent Sox2
transcription in the absence of enhancer proximity. eLife. 2019;8:
e41769.
48. Smith E, Shilatifard A. Enhancer biology and enhanceropathies. Nat
Struct Mol Biol. 2014;21:210–219.
49. de la Torre-Ubieta L, et al. The dynamic landscape of open chromatin
during human cortical neurogenesis. Cell. 2018;172:289–304.e18.
50. An J-Y, et al. Genome-wide de novo risk score implicates promoter
variation in autism spectrum disorder. Science. 2018;362:eaat6576.
51. Short PJ, et al. De novo mutations in regulatory elements in
neurodevelopmental disorders. Nature. 2018;555:611–616.
52. Perenthaler E, Yousefi S, Niggl E, Barakat TS. Beyond the exome: the
noncoding genome and enhancers in neurodevelopmental disorders and
malformations of cortical development. Front Cell Neurosci.
2019;13:352.
53. Carullo NVN, Day JJ. Genomic enhancers in brain health and disease.
Genes. 2019;10:43.
54. Nord AS, West AE. Neurobiological functions of transcriptional
enhancers. Nat Neurosci. 2020;23:5–14.
55. Bonev B, Cavalli G. Organization and function of the 3D genome. Nat Rev
Genet 2016;17:661–678.
56. Dixon JR, et al. Chromatin architecture reorganization during stem cell
differentiation. Nature. 2015;518:331–336.
57. Rajarajan P. et al. Neuron-specific signatures in the chromosomal
connectome associated with schizophrenia risk. Science. 2018;362:
eaat4311.
58. Gregor A, et al. De novo mutations in the genome organizer CTCF cause
intellectual disability. Am J Hum Genet. 2013;93:124–131.
59. Gabriele M, et al. YY1 haploinsufficiency causes an intellectual disability
syndrome featuring transcriptional and chromatin dysfunction. Am J Hum
Genet. 2017;100:907–925.
60. Lehalle D, et al. STAG1 mutations cause a novel cohesinopathy
characterised by unspecific syndromic intellectual disability. J Med
Genet. 2017;54:479–488.
61. Liu J, Krantz I. Cornelia de Lange syndrome, cohesin, and beyond. Clin
Genet. 2009;76:303–314.
62. Middelkamp S, et al. Prioritization of genes driving congenital
phenotypes of patients with de novo genomic structural variants.
Genome Med. 2019;11:79.
63. Gasperini M, Tome JM, Shendure J. Towards a comprehensive catalogue
of validated and target-linked human enhancers. Nat Rev Genet.
2020;21:292–310.
64. Hu WF, Chahrour MH, Walsh CA. The diverse genetic landscape of
neurodevelopmental disorders. Annu Rev Genomic Hum Genet
2014;15:195–213.
65. Vissers LELM, Gilissen C, Veltman JA. Genetic studies in intellectual
disability and related disorders. Nat Rev Genet 2016;17:9–18.
66. Gilissen C, et al. Genome sequencing identifies major causes of severe
intellectual disability. Nature. 2014;511:344–347.
67. Gaugler T, et al. Most genetic risk for autism resides with common
variation. Nat Genet. 2014;46:881–885.
68. Turner TN, Eichler EE. The role of de novo noncoding regulatory
mutations in neurodevelopmental disorders. Trends Neurosci. 2019;42:
115–127.
69. Redin C, et al. The genomic landscape of balanced cytogenetic
abnormalities associated with human congenital anomalies. Nat Genet.
2017;49:36–45.
70. Han L, et al. Functional annotation of rare structural variation in the
human brain. Nat Commun. 2020;11:2990.
71. Doan RN, et al. Mutations in human accelerated regions disrupt cognition
and social behavior. Cell. 2016;167:341–354.e12.
72. Monlong J, et al. Global characterization of copy number variants in
epilepsy patients from whole genome sequencing. PLoS Genet. 2018;14:
e1007285.
73. Chiang C, et al. The impact of structural variation on human gene
expression. Nat Genet. 2017;49:692–699.
74. Lupiáñez DG, et al. Disruptions of topological chromatin domains cause
pathogenic rewiring of gene-enhancer interactions. Cell. 2015;161:
1012–1025.
75. Despang A, et al. Functional dissection of the Sox9–Kcnj2 locus identifies
nonessential and instructive roles of TAD architecture. Nat Genet.
2019;51:1263–1271.
76. Sutherland HF, et al.Identification of a novel transcript disrupted by a
balanced translocation associated with DiGeorge syndrome. Am J Hum
Genet. 1996;59:23–31.
77. Meng Q, et al. The DGCR5 long noncoding RNA may regulate expression
of several schizophrenia-related genes. Sci Transl Med. 2018;10:
eaat6912.
78. Ang CE, et al. The novel lncRNA lnc-NR2F1 is pro-neurogenic and
mutated in human neurodevelopmental disorders. eLife. 2019;8:e41770.
79. Ross PJ. et al. Synaptic dysfunction in human neurons with autism-
associated deletions in PTCHD1-AS. Biol Psychiatry. 2020;87:139–149.
80. Cappuccio G, et al. Microdeletion of pseudogene chr14.232.a affects
LRFN5 expression in cells of a patient with autism spectrum disorder. Eur J
Hum Genet. 2019;27:1475–1480.
81. Talkowski ME. et al.Disruption of a large intergenic noncoding RNA in
subjects with neurodevelopmental disabilities. Am J Hum Genet.
2012;91:1128–1134.
82. Dornelles-Wawruk H, et al. A balanced reciprocal translocation t(2;9)
(p25;q13) disrupting the LINC00299 gene in a patient with intellectual
disability. Mol Syndromol. 2019;10:234–238.
83. Ng S-Y, Johnson R, Stanton LW. Human long noncoding RNAs promote
pluripotency and neuronal differentiation by association with chromatin
modifiers and transcription factors. EMBO J. 2012;31:522–533.
84. Ng S-Y, Bogu GK, Soh BS, Stanton LW. The long noncoding RNA RMST
interacts with SOX2 to regulate neurogenesis. Mol Cell. 2013;51:
349–359.
85. Stamou M, et al. A balanced translocation in Kallmann syndrome
implicates a long noncoding RNA, RMST, as a GnRH neuronal regulator. J
Clin Endocrinol Metab. 2020;105:e231–e244.
86. Kagami M, et al. Deletions and epimutations affecting the human
14q32.2 imprinted region in individuals with paternal and maternal upd
(14)-like phenotypes. Nat Genet. 2008;40:237–242.
87. Bieth E, et al. Highly restricted deletion of the SNORD116 region is
implicated in Prader–Willi syndrome. Eur J Hum Genet. 2015;23:
252–255.
88. Burnett LC, et al. Loss of the imprinted, noncoding Snord116 gene cluster
in the interval deleted in the Prader Willi syndrome results in murine
neuronal and endocrine pancreatic developmental phenotypes. Hum Mol
Genet. 2017;26:4606–4616.
89. Coulson RL, et al. Prader–Willi locus Snord116 RNA processing requires
an active endogenous allele and neuron-specific splicing by Rbfox3/
NeuN. Hum Mol Genet. 2018;27:4051–4060.
90. Poeta L, Drongitis D, Verrillo L, Miano MG. Dna hypermethylation and
unstable repeat diseases: A paradigm of transcriptional silencing to decipher
the basis of pathogenic mechanisms. Genes (Basel). 2020;11:1–18.
91. Sun JH, et al. Disease-associated short tandem repeats co-localize with
chromatin domain boundaries. Cell. 2018;175:224–238.e15.
92. LaCroix AJ, et al. GGC repeat expansion and exon 1 methylation of
XYLT1 is a common pathogenic variant in Baratela–Scott syndrome. Am J
Hum Genet. 2019;104:35–44.
93. Roessler E, et al. Cytogenetic rearrangements involving the loss of the
Sonic Hedgehog gene at 7q36 cause holoprosencephaly. Hum Genet.
1997;100:172–181.
D’HAENE and VERGULT REVIEW ARTICLE
GENETICS in MEDICINE | Volume 23 | Number 1 | January 2021 45
94. Benabdallah NS, et al. SBE6: a novel long-range enhancer involved in
driving sonic hedgehog expression in neural progenitor cells. Open Biol.
2016;6:160197.
95. Visel A, Minovitsky S, Dubchak I, Pennacchio LA. VISTA Enhancer
Browser—a database of tissue-specific human enhancers. Nucleic Acids
Res. 2007;35:D88–D92.
96. Wang Y, et al. The 3D Genome Browser: a web-based browser for
visualizing 3D genome organization and long-range chromatin
interactions. Genome Biol. 2018;19:151.
97. Mehrjouy MM, et al. Regulatory variants of FOXG1 in the context of its
topological domain organisation. Eur J Hum Genet. 2018;26:186–196.
98. D’haene E, et al. A neuronal enhancer network upstream of MEF2C is
compromised in patients with Rett-like characteristics. Hum Mol Genet.
2019;28:818–827.
99. FitzPatrick DR, et al. Identification of SATB2 as the cleft palate gene on
2q32-q33. Hum Mol Genet. 2003;12:2491–2501.
100. Rainger JK, et al. Disruption of SATB2 or its long-range cis-regulation by
SOX9 causes a syndromic form of Pierre Robin sequence. Hum Mol
Genet. 2014;23:2569–2579.
101. Gordon CT, et al. Identification of novel craniofacial regulatory domains
located far upstream of SOX9 and disrupted in Pierre Robin sequence.
Hum Mutat. 2014;35:1011–1020.
102. Franke M, et al. Formation of new chromatin domains determines
pathogenicity of genomic duplications. Nature. 2016;538:265–269.
103. Ibrahim DM, Mundlos S. Three-dimensional chromatin in disease: what
holds us together and what drives us apart? Curr Opin Cell Biol.
2020;64:1–9.
104. Bunyan DJ, et al. X-linked dominant congenital ptosis cosegregating with
an interstitial insertion of a chromosome 1p21.3 fragment into a
quasipalindromic sequence in Xq27.1. Open J Genet. 2014;04:415–425.
105. Haines B, et al. Interchromosomal insertional translocation at Xq26.3
alters SOX3 expression in an individual with XX male sex reversal. J Clin
Endocrinol Metab. 2015;100:E815–E820.
106. Sutton E, et al. Identification of SOX3 as an XX male sex reversal gene in
mice and humans. J Clin Invest. 2011;121:328–341.
107. Birnbaum RY, et al. Functional characterization of tissue-specific
enhancers in the DLX5/6 locus. Hum Mol Genet. 2012;21:4930–4938.
108. Johnson KR, et al. Deletion of a long-range Dlx5 enhancer disrupts inner
ear development in mice. Genetics. 2018;208:1165–1179.
109. Rasmussen MB, et al. Phenotypic subregions within the split-hand/foot
malformation 1 locus. Hum Genet. 2016;135:345–357.
110. Idrees F, et al. A novel homeobox mutation in the PITX2 gene in a family
with Axenfeld-Rieger syndrome associated with brain, ocular, and
dental phenotypes. Am J Med Genet B 2006;141B:184–191.
111. Trembath DG, et al. Analysis of two translocation breakpoints
and identification of a negative regulatory element in patients with
Rieger’s syndrome. Birth Defects Res A Clin Mol Teratol. 2004;70:
82–91.
112. Protas ME, et al. Mutations of conserved noncoding elements of PITX2
in patients with ocular dysgenesis and developmental glaucoma. Hum
Mol Genet. 2017;26:3630–3638.
113. Kleinjan DA, et al. Long-range downstream enhancers are essential for
Pax6 expression. Dev Biol. 2006;299:563–581.
114. Laugsch M, et al. Modeling the pathological long-range regulatory
effects of human structural variation with patient-specific hiPSCs. Cell
Stem Cell. 2019;24:736–752.e12.
115. Lessel D, et al. BCL11B mutations in patients affected by a
neurodevelopmental disorder with reduced type 2 innate lymphoid
cells. Brain. 2018;141:2299–2311.
116. Melo US, et al.Hi-C identifies complex genomic rearrangements and TAD-
shuffling in developmental diseases. Am J Hum Genet. 2020;106:872–884.
117. Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants:
changing the landscape of chromosomes and design of disease studies.
Hum Mol Genet. 2006;15:R57–R66.
118. Barakat TS, et al. Functional dissection of the enhancer repertoire in
human embryonic stem cells. Cell Stem Cell. 2018;23:276–288.e8.
119. Wang X. et al. High-resolution genome-wide functional dissection of
transcriptional regulatory regions and nucleotides in human. Nat
Commun. 2018;9:5380.
120. Gasperini M, et al. A genome-wide framework for mapping gene
regulation via cellular genetic screens. Cell. 2019;176:377–390.e19.
121. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome
Biol. 2017;18:1–15.
122. Andersson R, et al. An atlas of active enhancers across human cell types
and tissues. Nature. 2014;507:455–461.
123. Kundaje A, et al. Integrative analysis of 111 reference human
epigenomes. Nature. 2015;518:317–330.
124. Li M, et al. Integrative functional genomic analysis of human brain
development and neuropsychiatric risks. Science. 2018;362:eaat7615.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License,which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made. The
images or other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and
your intended use is not permitted by statutory regulation or exceeds the
permitted use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/.
© The Author(s) 2020
REVIEW ARTICLE D’HAENE and VERGULT
46 Volume 23 | Number 1 | January 2021 | GENETICS in MEDICINE
